Dartmouth Cancer Center Appoints Dr. Roy S. Herbst as New Director
Dartmouth Cancer Center Appoints Dr. Roy S. Herbst as New Director
The Dartmouth Cancer Center (DCC) has announced a significant leadership transition.
Roy S.
Herbst as its sixth director, with his tenure officially beginning on July 13, 2026.
Herbst joins the institution from the Yale Cancer Center, where he was a prominent leader in medical oncology and pharmacology.
Herbst is celebrated for his groundbreaking work in precision medicine and immunotherapy, particularly regarding lung cancer.
He is widely recognized for leading innovative clinical trials like 'BATTLE' and 'Lung-MAP,' which helped transform how researchers match targeted therapies to specific patient biomarkers.
His primary goals include expanding access to advanced clinical trials and strengthening cancer care across New England, with a special focus on serving rural populations.
The DCC is a prestigious National Cancer Institute-designated comprehensive center and the only one of its kind in the region located outside a major urban hub.
